|
1
|
Linossi EM, Babon JJ, Hilton DJ and
Nicholson SE: Suppression of cytokine signaling: the SOCS
perspective. Cytokine Growth Factor Rev. 24:241–248. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shi J and Wei L: Regulation of JAK/STAT
signalling by SOCS in the myocardium. Cardiovasc Res. 96:345–347.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tamiya T, Kashiwagi I, Takahashi R,
Yasukawa H and Yoshimura A: Suppressors of cytokine signaling
(SOCS) proteins and JAK/STAT pathways: regulation of T-cell
inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol.
31:980–985. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoshimura A, Suzuki M, Sakaguchi R, Hanada
T and Yasukawa H: SOCS, inflammation, and autoimmunity. Front
Immunol. 3:202012. View Article : Google Scholar
|
|
5
|
Bhattacharyya S, Zhao Y, Kay TW and Muglia
LJ: Glucocorticoids target suppressor of cytokine signaling 1
(SOCS1) and type 1 interferons to regulate Toll-like
receptor-induced STAT1 activation. Proc Natl Acad Sci USA.
108:9554–9559. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Satou R, Miyata K, Gonzalez-Villalobos RA,
Ingelfinger JR, Navar LG and Kobori H: Interferon-γ biphasically
regulates angiotensinogen expression via a JAK-STAT pathway and
suppressor of cytokine signaling 1 (SOCS1) in renal proximal
tubular cells. FASEB J. 26:1821–1830. 2012.
|
|
7
|
Hong B, Ren W, Song XT, Evel-Kabler K,
Chen SY and Huang XF: Human SOCS1 controls immuno-stimulatory
activity of monocyte derived dendritic cells. Cancer Res.
69:8076–8084. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu Q, Qin X, Qian G, et al: SOCS1
silencing can break high-dose dendritic cell immuno therapy induced
immune tolerance. Mol Med Report. 1:61–70. 2008.PubMed/NCBI
|
|
9
|
Ortiz-Muñoz G, Martin-Ventura JL,
Hernandez-Vargas P, et al: Suppressors of cytokine signaling
modulate JAK/STAT mediated cell responses during atherosclerosis.
Arterioscler Thromb Vasc Biol. 29:525–531. 2009.PubMed/NCBI
|
|
10
|
Tomita S, Ishibashi K, Hashimoto K, et al:
Suppression of SOCS3 increases susceptibility of renal cell
carcinoma to interferon-α. Cancer Sci. 102:57–63. 2011.PubMed/NCBI
|
|
11
|
Evel-Kabler K, Song XT, Aldrich M, Huang
XF and Chen SY: SOCS1 restricts dendritic cells’ ability to break
self tolerance and induce antitumor immunity by regulating IL-12
production and signaling. J Clin Inves. 116:90–100. 2006.
|
|
12
|
Song XT, Evel-Kabler K, Rollins L, Aldrich
M, Gao F, Huang XF and Chen SY: An alternative and effective HIV
vaccination approach based on inhibition of antigen presentation
attenuators in dendritic cells. PLoS Med. 3:e112006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chu PY, Yeh CM, Hsu NC, Chang YS, Chang JG
and Yeh KT: Epigenetic alteration of the SOCS1 gene in
hepatocellular carcinoma. Swiss Med Wkly. 140:w130652010.PubMed/NCBI
|
|
14
|
Liu S, Ren S, Howell P, Fodstad O and
Riker AI: Identification of novel epigenetically modified genes in
human melanoma via promoter methylation gene profiling. Pigment
Cell Melanoma Res. 21:545–558. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Neuwirt H, Puhr M, Santer FR, et al:
Suppressor of cytokine signaling (SOCS)-1 is expressed in human
prostate cancer and exerts growth-inhibitory function through
down-regulation of cyclins and cyclin-dependent kinases. Am J
Pathol. 174:1921–1930. 2009. View Article : Google Scholar
|
|
16
|
Lesinski GB, Zimmerer JM, Kreiner M, et
al: Modulation of SOCS protein expression influences the interferon
responsiveness of human melanoma cells. BMC Cancer. 10:1422010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kusunoki H, Okuma K and Hamaguchi I:
Estimation of lactose interference in vaccines and a proposal of
methodological adjustment of total protein determination by the
lowry method. Jpn J Infect Dis. 65:489–494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Starska K, Forma E, Lewy-Trenda I,
Stasikowska O, Bryś M, Krajewska WM and Łukomski M: The expression
of SOCS1 and TLR4-NFkappaB pathway molecules in neoplastic cells as
potential biomarker for the aggressive tumor phenotype in laryngeal
carcinoma. Folia Histochem Cytobiol. 47:401–410. 2009.
|
|
19
|
Ko E, Kim SJ, Joh JW, Park CK, Park J and
Kim DH: CpG island hypermethylation of SOCS-1 gene is inversely
associated with HBV infection in hepatocellular carcinoma. Cancer
Lett. 271:240–250. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cooper JC, Shi M, Chueh FY, Venkitachalam
S and Yu CL: Enforced SOCS1 and SOCS3 expression attenuates
Lck-mediated cellular transformation. Int J Oncol. 36:1201–1208.
2010.PubMed/NCBI
|
|
21
|
Huang FJ, Steeg PS, Price JE, et al:
Molecular basis for the critical role of suppressor of cytokine
signaling-1 in melanoma brain metastasis. Cancer Res. 68:9634–9642.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sutherland KD, Lindeman GJ, Choong DY, et
al: Differential hypermethylation of SOCS genes in ovarian and
breast carcinomas. Oncogene. 23:7726–7733. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sasi W, Jiang WG, Sharma A and Mokbel K:
Higher expression levels of SOCS 1,3,4,7 are associated with
earlier tumour stage and better clinical outcome in human breast
cancer. BMC Cancer. 10:1782010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Neuwirt H, Puhr M, Santer FR, et al:
Suppressor of cytokine signaling (SOCS)-1 is expressed in human
prostate cancer and exerts growth-inhibitory function through
down-regulation of cyclins and cyclin-dependent kinases. Am J
Pathol. 174:1921–1930. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Scutti JA, Matsuo AL, Pereira FV, et al:
Role of SOCS-1 gene on melanoma cell growth and tumor development.
Transl Oncol. 4:101–109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guenterberg KD, Lesinski GB, Mundy-Bosse
BL, Karpa VI, Jaime-Ramirez AC, Wei L and Carson WE III: Enhanced
anti-tumor activity of interferon-alpha in SOCS1-deficient mice is
mediated by CD4- and CD8- T cells. Cancer Immunol Immunother.
60:1281–1288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Olière S, Hernandez E, Lézin A, et al:
HTLV-1 evades type I interferon antiviral signaling by inducing the
suppressor of cytokine signaling 1 (SOCS1). PLoS Pathog.
6:e10011772010.PubMed/NCBI
|
|
28
|
Shao RX, Zhang L, Hong Z, et al: SOCS1
abrogates IFN’s antiviral effect on hepatitis C virus replication.
Antiviral Res. 97:101–107. 2013.
|
|
29
|
Li A, Song W, Qian J, et al: MiR-122
modulates type I interferon expression through blocking suppressor
of cytokine signaling 1. Int J Biochem Cell Biol. 45:858–865. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mathieu MG, Miles AK, Ahmad M, et al: The
helicase HAGE prevents interferon-α-induced PML expression in
ABCB5+ malignant melanoma-initiating cells by promoting the
expression of SOCS1. Cell Death Dis. 5:e10612014.PubMed/NCBI
|
